1. Richardson JL, Stephens S, Yates LM, Diav-Citrin O, Arnon J, Beghin D, Kayser A, Kennedy D, Cupitt D, Te Winkel B, Peltonen M, Kaplan YC, Thomas SH. Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services. Reprod Toxicol. 2016 Nov 13;67:26-34.
  2. Keskin-Arslan E, Kaplan YC. Comment on the case report "Possible association between acetazolamide administration during pregnancy and multiple congenital malformations". Drug Des Devel Ther. 2016 Nov 10;10:3681-3683.
  3. Kaplan YC, Keskin-Arslan E, Acar S, Sozmen K. Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis. Reprod Toxicol. 2016 Sep 22;66:31-43.
  4. Kaplan YC. Comment on "Identifying Human Teratogens: An Update". J Pediatr Genet. 2016 Sep;5(3):181-2.
  5. Kaplan YC, Abdelkader N. Valproate prescribing trends for non-epilepsy indications in women of reproductive age warrants effective measures and increased surveillance. Seizure. 2016 Aug;40:13-4.
  6. Kaplan YC, Spigset O. Comment to the article 'Use of psychotropic drugs during pregnancy and breast-feeding'. Acta Psychiatr Scand. 2016 May;133(5):428-9.
  7. Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 May;81(5):835-48.
  8. Kaplan YC, Küçüksolak G. Folic acid, body mass index and cardiovascular malformations. Turk Pediatri Ars. 2016 Mar 1;51(1):60-1.
  9. Yöntem S, Maden-Tastan B, Kaplan YC. Comment on: "Indigenous Medicine Use for Sex Selection During Pregnancy and Risk of Congenital Malformations: A Population-Based Case-Control Study in Haryana, India". Drug Saf. 2016 Jan;39(1):89-90.
Menüyü Kapat